Vetoquinol SA Logo

Vetoquinol SA

VETO.PA

(2.2)
Stock Price

83,20 EUR

11.99% ROA

10.76% ROE

18.25x PER

Market Cap.

1.013.966.920,00 EUR

3.34% DER

0.99% Yield

10.5% NPM

Vetoquinol SA Stock Analysis

Vetoquinol SA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vetoquinol SA Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a minimal amount of debt (4%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

4 ROE

The stock's ROE falls within an average range (10.37%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 PBV

The stock's PBV ratio (2.16x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.416), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Vetoquinol SA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vetoquinol SA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Vetoquinol SA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vetoquinol SA Revenue
Year Revenue Growth
2005 196.617.000
2006 211.591.000 7.08%
2007 233.364.000 9.33%
2008 234.395.000 0.44%
2009 257.057.000 8.82%
2010 282.041.000 8.86%
2011 284.137.000 0.74%
2012 298.293.000 4.75%
2013 299.727.000 0.48%
2014 315.298.000 4.94%
2015 342.612.000 7.97%
2016 350.354.000 2.21%
2017 352.173.000 0.52%
2018 367.941.000 4.29%
2019 395.990.000 7.08%
2019 395.990.000 0%
2020 427.467.000 7.36%
2021 521.272.000 18%
2022 539.779.000 3.43%
2023 1.092.112.000 50.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vetoquinol SA Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1.961.000 100%
2012 1.715.000 -14.34%
2013 20.000.000 91.43%
2014 21.900.000 8.68%
2015 22.100.000 0.9%
2016 24.200.000 8.68%
2017 25.500.000 5.1%
2018 26.410.000 3.45%
2019 2.577.000 -924.84%
2019 29.982.000 91.4%
2020 28.400.000 -5.57%
2021 31.000.000 8.39%
2022 25.000.000 -24%
2023 160.400.000 84.41%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vetoquinol SA General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 15.073.280
2006 18.058.580 16.53%
2007 0 0%
2008 0 0%
2009 0 0%
2010 3.857.000 100%
2011 4.183.000 7.79%
2012 35.766.000 88.3%
2013 36.187.000 1.16%
2014 38.251.000 5.4%
2015 40.965.000 6.63%
2016 46.196.000 11.32%
2017 43.812.000 -5.44%
2018 49.670.000 11.79%
2019 5.026.000 -888.26%
2019 55.055.000 90.87%
2020 54.061.000 -1.84%
2021 66.625.000 18.86%
2022 71.951.000 7.4%
2023 -89.844.000 180.08%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vetoquinol SA EBITDA
Year EBITDA Growth
2005 29.711.720
2006 30.024.420 1.04%
2007 38.124.000 21.25%
2008 48.086.000 20.72%
2009 51.281.000 6.23%
2010 45.689.000 -12.24%
2011 44.282.000 -3.18%
2012 43.558.000 -1.66%
2013 44.408.000 1.91%
2014 47.388.000 6.29%
2015 51.308.000 7.64%
2016 55.521.000 7.59%
2017 57.090.000 2.75%
2018 60.019.000 4.88%
2019 65.596.000 8.5%
2019 58.794.000 -11.57%
2020 78.370.000 24.98%
2021 110.144.000 28.85%
2022 110.864.000 0.65%
2023 139.432.000 20.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vetoquinol SA Gross Profit
Year Gross Profit Growth
2005 127.861.000
2006 138.681.000 7.8%
2007 103.511.000 -33.98%
2008 158.146.000 34.55%
2009 170.891.000 7.46%
2010 123.179.000 -38.73%
2011 120.281.000 -2.41%
2012 186.103.000 35.37%
2013 149.770.000 -24.26%
2014 160.457.000 6.66%
2015 173.617.000 7.58%
2016 180.069.000 3.58%
2017 186.718.000 3.56%
2018 196.032.000 4.75%
2019 262.463.000 25.31%
2019 205.888.000 -27.48%
2020 123.976.000 -66.07%
2021 167.373.000 25.93%
2022 172.368.000 2.9%
2023 625.144.000 72.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vetoquinol SA Net Profit
Year Net Profit Growth
2005 12.440.720
2006 15.824.000 21.38%
2007 18.642.000 15.12%
2008 18.564.000 -0.42%
2009 18.207.000 -1.96%
2010 22.255.000 18.19%
2011 22.695.000 1.94%
2012 22.569.000 -0.56%
2013 23.580.000 4.29%
2014 25.766.000 8.48%
2015 24.156.000 -6.67%
2016 27.827.000 13.19%
2017 34.831.000 20.11%
2018 36.259.000 3.94%
2019 28.217.000 -28.5%
2019 28.589.000 1.3%
2020 19.221.000 -48.74%
2021 62.861.000 69.42%
2022 47.995.000 -30.97%
2023 93.336.000 48.58%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vetoquinol SA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 130
2006 2 -12900%
2007 2 0%
2008 2 0%
2009 2 0%
2010 2 0%
2011 2 0%
2012 2 0%
2013 2 0%
2014 2 50%
2015 2 0%
2016 2 0%
2017 3 0%
2018 3 33.33%
2019 2 -50%
2019 2 0%
2020 2 -100%
2021 5 80%
2022 4 -25%
2023 8 42.86%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vetoquinol SA Free Cashflow
Year Free Cashflow Growth
2005 19.540.000
2006 -2.182.000 995.51%
2007 28.777.000 107.58%
2008 13.036.000 -120.75%
2009 32.375.000 59.73%
2010 26.603.000 -21.7%
2011 20.372.000 -30.59%
2012 25.121.000 18.9%
2013 21.634.000 -16.12%
2014 31.061.000 30.35%
2015 27.881.000 -11.41%
2016 33.765.000 17.43%
2017 30.143.000 -12.02%
2018 26.608.000 -13.29%
2019 9.422.750 -182.38%
2019 42.578.000 77.87%
2020 -53.449.000 179.66%
2021 56.764.000 194.16%
2022 39.895.000 -42.28%
2023 50.575.000 21.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vetoquinol SA Operating Cashflow
Year Operating Cashflow Growth
2005 30.014.000
2006 23.356.000 -28.51%
2007 37.215.000 37.24%
2008 21.903.000 -69.91%
2009 40.046.000 45.31%
2010 34.360.000 -16.55%
2011 29.992.000 -14.56%
2012 34.209.000 12.33%
2013 28.106.000 -21.71%
2014 41.298.000 31.94%
2015 38.897.000 -6.17%
2016 43.205.000 9.97%
2017 41.225.000 -4.8%
2018 37.884.000 -8.82%
2019 13.006.000 -191.28%
2019 52.024.000 75%
2020 92.012.000 43.46%
2021 89.167.000 -3.19%
2022 62.392.000 -42.91%
2023 58.553.000 -6.56%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vetoquinol SA Capital Expenditure
Year Capital Expenditure Growth
2005 10.474.000
2006 25.538.000 58.99%
2007 8.438.000 -202.65%
2008 8.867.000 4.84%
2009 7.671.000 -15.59%
2010 7.757.000 1.11%
2011 9.620.000 19.37%
2012 9.088.000 -5.85%
2013 6.472.000 -40.42%
2014 10.237.000 36.78%
2015 11.016.000 7.07%
2016 9.440.000 -16.69%
2017 11.082.000 14.82%
2018 11.276.000 1.72%
2019 3.583.250 -214.69%
2019 9.446.000 62.07%
2020 145.461.000 93.51%
2021 32.403.000 -348.91%
2022 22.497.000 -44.03%
2023 7.978.000 -181.99%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vetoquinol SA Equity
Year Equity Growth
2005 86.820.000
2006 111.148.000 21.89%
2007 127.871.000 13.08%
2008 137.054.000 6.7%
2009 154.946.000 11.55%
2010 184.273.000 15.91%
2011 211.291.000 12.79%
2012 228.009.000 7.33%
2013 235.955.000 3.37%
2014 268.396.000 12.09%
2015 289.493.000 7.29%
2016 316.475.000 8.53%
2017 335.728.000 5.73%
2018 363.084.000 7.53%
2019 385.981.000 5.93%
2020 371.829.000 -3.81%
2021 441.354.000 15.75%
2022 484.663.000 8.94%
2023 527.110.000 8.05%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vetoquinol SA Assets
Year Assets Growth
2005 199.717.000
2006 210.623.000 5.18%
2007 228.405.000 7.79%
2008 236.431.000 3.39%
2009 283.666.000 16.65%
2010 309.449.000 8.33%
2011 318.311.000 2.78%
2012 356.438.000 10.7%
2013 351.831.000 -1.31%
2014 419.363.000 16.1%
2015 412.476.000 -1.67%
2016 439.172.000 6.08%
2017 443.970.000 1.08%
2018 465.583.000 4.64%
2019 511.468.000 8.97%
2020 646.092.000 20.84%
2021 624.561.000 -3.45%
2022 651.848.000 4.19%
2023 692.232.000 5.83%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vetoquinol SA Liabilities
Year Liabilities Growth
2005 112.897.000
2006 99.475.000 -13.49%
2007 100.534.000 1.05%
2008 99.377.000 -1.16%
2009 128.720.000 22.8%
2010 125.176.000 -2.83%
2011 107.020.000 -16.97%
2012 128.429.000 16.67%
2013 115.876.000 -10.83%
2014 150.967.000 23.24%
2015 122.983.000 -22.75%
2016 122.697.000 -0.23%
2017 108.242.000 -13.35%
2018 102.499.000 -5.6%
2019 125.487.000 18.32%
2020 274.263.000 54.25%
2021 183.207.000 -49.7%
2022 167.185.000 -9.58%
2023 165.122.000 -1.25%

Vetoquinol SA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
44.72
Net Income per Share
4.69
Price to Earning Ratio
18.25x
Price To Sales Ratio
1.92x
POCF Ratio
11.32
PFCF Ratio
14.11
Price to Book Ratio
1.92
EV to Sales
1.67
EV Over EBITDA
10.25
EV to Operating CashFlow
9.87
EV to FreeCashFlow
12.3
Earnings Yield
0.05
FreeCashFlow Yield
0.07
Market Cap
1,01 Bil.
Enterprise Value
0,88 Bil.
Graham Number
68.59
Graham NetNet
9.89

Income Statement Metrics

Net Income per Share
4.69
Income Quality
1.61
ROE
0.11
Return On Assets
0.08
Return On Capital Employed
0.1
Net Income per EBT
0.75
EBT Per Ebit
1.33
Ebit per Revenue
0.11
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
-0.04
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.37
Operating Profit Margin
0.11
Pretax Profit Margin
0.14
Net Profit Margin
0.1

Dividends

Dividend Yield
0.01
Dividend Yield %
0.99
Payout Ratio
0.17
Dividend Per Share
0.85

Operating Metrics

Operating Cashflow per Share
7.57
Free CashFlow per Share
6.07
Capex to Operating CashFlow
0.2
Capex to Revenue
0.03
Capex to Depreciation
0.53
Return on Invested Capital
0.08
Return on Tangible Assets
0.12
Days Sales Outstanding
77.51
Days Payables Outstanding
45.93
Days of Inventory on Hand
113.23
Receivables Turnover
4.71
Payables Turnover
7.95
Inventory Turnover
3.22
Capex per Share
1.49

Balance Sheet

Cash per Share
12,35
Book Value per Share
44,54
Tangible Book Value per Share
25.19
Shareholders Equity per Share
44.53
Interest Debt per Share
1.53
Debt to Equity
0.03
Debt to Assets
0.03
Net Debt to EBITDA
-1.5
Current Ratio
2.61
Tangible Asset Value
0,30 Bil.
Net Current Asset Value
0,20 Bil.
Invested Capital
542733000
Working Capital
0,22 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,10 Bil.
Average Payables
0,07 Bil.
Average Inventory
109807500
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vetoquinol SA Dividends
Year Dividends Growth
2007 0
2008 1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 1 0%
2023 1 0%
2024 1 0%

Vetoquinol SA Profile

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

CEO
Mr. Alain Masson
Employee
2.519
Address
Magny-Vernois
Lure, 70204

Vetoquinol SA Executives & BODs

Vetoquinol SA Executives & BODs
# Name Age
1 Philippe Gruet
Chief Scientific Officer
70
2 Sandrine Perrier
Chief Information Officer
70
3 Laurent Thore
Director of Partnerships, Legal Affairs & Risks
70
4 Xavier Berthet
Director of Group Communications
70
5 Ms. Isabelle Proust-Cabrera
Group Director of Human Resources
70
6 Mr. Alain Masson
Deputy Chief Executive Officer & Pharmacist Manager
70
7 Mr. Matthieu Frechin
Chief Executive Officer & Non-Independent Chairman of the Board
70
8 Mr. Regis Vimal du Monteil
Chief Financial Officer
70
9 Mr. Dominique Derveaux
Chief Operations Officer
70

Vetoquinol SA Competitors

Virbac SA Logo
Virbac SA

VIRP.PA

(2.8)
Thermador Groupe SA Logo
Thermador Groupe SA

THEP.PA

(4.0)
Robertet SA Logo
Robertet SA

RBT.PA

(3.2)
Trigano S.A. Logo
Trigano S.A.

TRI.PA

(3.8)
Neurones S.A. Logo
Neurones S.A.

NRO.PA

(3.5)